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ván  Villar Balboab, Oriol Cunillera Puértolasc, Jesús Almeda Ortegac
Equip  d’Atenció  Primària  Florida  Nord,  Institut  Català  de  la  Salut,  Hospitalet  de  Llobregat,  Barcelona,  Spain
Equip  d’Atenció  Primària  Florida  Sud,  Institut  Català  de  la  Salut,  Hospitalet  de  Llobregat,  Barcelona,  Spain
Unitat  de  Suport  a  la  Recerca  Metropolitana  Sud,  Institut  Universitari  d’Investigació  en  Atenció  Primària  Jordi  Gol  (IDIAP  Jordi
ol), Spain






Abstract  Patients  who  experience  both  vertigo  and  nystagmus  in  the  Dix-Hallpike  test  (DHT)
are diagnosed  with  objective  benign  paroxysmal  positional  vertigo  (BPPV).  This  test  provokes
only vertigo  in  between  11%  and  48%  of  patients,  who  are  diagnosed  with  subjective  BPPV.
Detection  of  nystagmus  has  important  diagnostic  and  prognostic  implications.  To  compare  the
characteristics  of  patients  diagnosed  with  objective  and  subjective  BPPV  in  primary  care.  Cross-
sectional  descriptive  study.  Two  urban  primary  care  centers.  Adults  (≥18  years)  diagnosed  with
objective or  subjective  BPPV  between  November  2012  and  January  2015.  DHT  results  (ver-
tigo or  vertigo  plus  nystagmus;  dependent  variable:  nistagmus  as  response  to  DHT),  age,  sex,
time since  onset,  previous  vertigo  episodes,  self-reported  vertigo  severity  (Likert  scale,  0--10),
comorbidities  (recent  viral  infection,  traumatic  brain  injury,  headache,  anxiety/depression,
hypertension,  diabetes  mellitus,  dyslipidemia,  cardiovascular  disease,  altered  thyroid  func-
tion, osteoporosis,  cervical  spondylosis,  neck  pain).  In  total,  134  patients  (76.1%  women)  with
a mean  age  of  52  years  were  included;  59.71%  had  subjective  BPPV.  Objective  BPPV  was  sig-
nificantly associated  with  hypertension,  antihypertensive  therapy,  and  cervical  spondylosis  in
the bivariate  analysis  and  with  cervical  spondylosis  (OR  =  3.94,  p  =  0.021)  and  antihypertensive
therapy (OR  3.02,  p  =  0.028)  in  the  multivariate  analysis.  Patients  with  subjective  BPPV  were
more likely  to  be  taking  benzodiazepines  [OR  0.24,  p  =  0.023].  The  prevalence  of  subjective
BPPV was  higher  than  expected.  Cervical  spondylosis  and  hypertensive  therapy  were  associatedbenzodiazepines  were  associated  with  subjective  BPPV.
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Detección  de  nistagmo  en  respuesta  a  la  prueba  de  Dix-Hallpike  en  atención  primaria:
una  comparación  entre  vértigo  posicional  paroxístico  benigno  subjetivo  y  objetivo
Resumen  A  los  pacientes  que  experimentan  tanto  vértigo  como  nistagmo  en  la  prueba  de  Dix-
Hallpike (DHT)  se  les  diagnostica  vértigo  posicional  paroxístico  benigno  objetivo  (VPPB).  Esta
prueba provoca  solamente  vértigo  entre  el  11  y  el  48%  de  los  pacientes  a  los  que  se  les  diag-
nostica VPPB  subjetivo.  La  detección  de  nistagmo  tiene  importantes  implicaciones  diagnósticas
y pronósticas.  Comparar  las  características  de  los  pacientes  diagnosticados  de  VPPB  objetivo  y
subjetivo  en  Atención  Primaria.  Estudio  descriptivo  transversal.  Ubicación:  2  centros  urbanos
de Atención  Primaria.  Participantes:  adultos  (≥18  años)  diagnosticados  de  VPPB  objetivo  o  sub-
jetivo entre  noviembre  del  2012  y  enero  del  2015.  Resultados  de  la  DHT  (vértigo  o  vértigo
más nistagmo;  variable  dependiente:  nistagmo  como  respuesta  a  la  DHT),  edad,  sexo,  tiempo
desde el  inicio,  episodios  de  vértigo  previos,  gravedad  del  vértigo  autoinformada  (escala  Likert,
0-10), comorbilidades  (infección  viral  reciente,  lesión  cerebral  traumática,  dolor  de  cabeza,
ansiedad/depresión,  hipertensión,  diabetes  mellitus,  dislipidemia,  enfermedad  cardiovascu-
lar, función  tiroidea  alterada,  osteoporosis,  espondilosis  cervical,  cervicalgia).  Se  incluyó  a  134
pacientes  (76,1%  mujeres)  con  una  edad  media  de  52  años.  El  59,71%  presentaba  VPPB  subjetivo.
El VPPB  objetivo  se  asoció  significativamente  con  hipertensión,  tratamiento  antihipertensivo  y
espondilosis  cervical  en  el  análisis  bivariado  y  con  espondilosis  cervical  (OR  =  3,94,  p  =  0,021)
y tratamiento  antihipertensivo  (OR  =  3,02,  p  =  0,028)  en  el  análisis  multivariado.  Los  pacientes
con VPPB  subjetivo  tenían  más  probabilidades  de  estar  tomando  benzodiacepinas  (OR  =  0,24,
p =  0,023).  La  prevalencia  de  VPPB  subjetivo  fue  superior  a  la  esperada.  La  espondilosis  cervical
y la  terapia  hipertensiva  se  asociaron  con  VPPB  objetivo,  mientras  que  las  benzodiacepinas  se
asociaron  con  VPPB  subjetivo.
©  2021  Los  Autores.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo
















































ertigo  is  a  common  complaint  that  places  a  considerable
urden  on  primary  care  services.1 Benign  paroxysmal  posi-
ional  vertigo  (BPPV)  accounts  for  between  17%  and  42%of
ll  cases,  with  an  annual  incidence  of  between  10.7  and  140
ases  per  100,000  inhabitants.2,3 BPPV  is  characterized  by
 short-lived  rotating  sensation  induced  by  changes  in  head
osition.  The  posterior  canal  is  the  main  canal  affected  (60%
o  90%  of  cases).4 Posterior  canal  BPPV  can  be  diagnosed  in
rimary  care  with  a  targeted  history,  a  basic  physical  exam-
nation,  and  administration  of  the  Dix-Hallpike  (DHT)  test.
his  test  is  considered  positive  when  it  triggers  both  symp-
oms  (vertigo)  and  nystagmus.  Thediagnosis  in  this  case  is
bjective  BPPV.5 The  test  may  also  be  considered  positive
hen  it  triggers  vertigo  only.  In  this  case,  the  patient  is
iagnosed  with  subjective  BPPV.6,7 Subjective  BPPV  is  very
ommon  and  accounts  for  between  11.5%8 and  48%9 of  all
ases  of  BPPV.  One  possible  explanation  for  the  absence
f  nystagmus  is  that  the  dislodged  otolithic  particles  in
he  posterior  semicircular  canal  may  be  sufficient  to  cause
ertigo  but  not  nystagmus.7 It  is  also  possible  that  mild  nys-
agmus  may  go  unnoticed  if  specialized  equipment,  such
s  videonystagmography  systems  or  Frenzel  goggles,  is  not
sed.6 The  likelihood  of  a  false-negative  result  is  there-
ore  greater  in  primary  care,  where  between  60%  and  80%
10f  patients  with  BPPV  are  seen. In  a  randomized  clini-
al  trial  analyzing  the  effectiveness  of  the  Epley  maneuver
n  the  treatment  of  posterior  canal  BPPV  in  primary  care,





n  patients  who  had  both  vertigo  and  nystagmus  at  base-
ine  (objective  BPPV).11 Detection  of  nystagmus  therefore
as  important  diagnostic  and  prognostic  implications  and
tudies  are  needed  to  investigate  factors  associated  with
hiscondition.12
The  aim  of  this  study  was  to  analyze  factors  associated
ith  the  presence  or  absence  of  nystagmus  in  the  DHT  in
rimary  care  patients  with  posterior  canal  BPPV.
ethod
tudy  design
escriptive,  cross-sectional  study  based  on  the  basal  visit  of
 clinical  trial  with  the  objective  to  demonstrate  the  effec-
iveness  of  the  Epley  maneuver  to  treat  PC-BPPV  in  primary
are.  ClinicalTrials.gov  Identifier:  NCT01969513.13
etting
wo  primary  care  centers  with  26  general  practitioners
erving  an  approximate  population  of  38,305  people  in
’Hospitalet  de  Llobregat  (Barcelona,  Spain).nclusion  criteria
atients  aged  18  years  or  older  with  posterior  canal  BPPV  and

























































































atients  who  had  neither  vertigo  nor  nystagmus  with  DHT
ere  excluded  from  the  study.
xclusion  criteria
uspected  Menière’s  disease,  labyrinthitis,  vestibular  neu-
onitis,  pregnancy,  breastfeeding,  and  contraindications  for
erformance  of  the  DHT  or  Epley  maneuver  or  treat-
ent  with  betahistine.  Patients  with  findings  suggestive  of
nvolvement  of  a  semicircular  canal  other  than  the  poste-
ior  canal  or  any  other  diagnosis,  such  as  vertigo  of  central
rigin,  were  also  excluded  and  referred  to  an  ear,  nose,  and
hroat  specialist.  Nineteen  of  the  patients  were  excluded
ollowing  recruitment  because  they  had  findings  consistent
ith  vestibular  migraine.  Although  this  possibility  was  not
ontemplated  in  the  initial  protocol,13 vestibular  migraine
s  very  common  and  findings  published  after  our  study  was
esigned  have  shown  that  this  condition  has  overlapping
ymptoms  with  BPPV.14
articipant  selection
onsecutive  patients  with  symptoms  consistent  with  a diag-
osis  of  posterior  canal  BPPV  were  recruited  by  GPs  at  the
wo  participating  primary  care  centers.  The  recruitment
eriod  was  November  2012  to  January  2015.
rocedures
he  recruiting  team  took  a  full  history  from  the  patients,
erformed  a  full  physical  examination,  and  revised  their
lectronic  health  records.  The  baseline  DHT  was  consid-
red  positive  if  it  triggered  vertigo  and  nystagmus  (objective
PPV)  or  vertigo  only  (subjective  BPPV)  when  performed  on
ither  the  right  or  left  side.
The  following  variables  were  recorded  for  all  patients:
 Dependent  variables:  presence  or  absence  of  nystagmus
in  the  DHT.
 Independent  variables:  age;  sex;  time  since  onset  of
symptoms,  self-reported  severity  of  vertigo  symptoms
on  a  Likert  scale  of  0--10,  where  0  corresponds  to  no
symptoms  and  10  to  the  worst  imaginable  symptoms);
history  of  recent  viral  infection,  traumatic  brain  injury,
headache,  anxiety/depression,  hypertension,  diabetes
mellitus,  dyslipidemia,  cardiovascular  disease,  altered
thyroid  function,  osteoporosis,  cervicalspondylosis,  neck
pain;  pharmacological  treatment  of  vertigo  (betahistine
as  monotherapy  or  combined  therapy  or  treatment  with
dimenhydrinate,  sulpiride,  or  thiethylperazine);  other
treatments  (anti-depressants,  benzodiazepines,  and  anti-
hypertensives).
nalysis  and  statistical  tests
he  sample  size  was  calculated  based  on  outcomes  not  pre-
ented  in  this  paper,  as  the  original  trial  was  designed  to
etermine  the  effectiveness  of  the  Epley  maneuver  in  the
reatment  of  posterior  canal  BPPV  in  primary  care.  There
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pley  maneuver  and  betahistine)  and  68  in  the  control  group
treated  with  a  sham  maneuver  and  betahistine).
Results  are  expressed  as  median  and  interquartile  range
or  numerical  variables  and  as  absolute  and  relative  fre-
uencies  for  binary  (indicator)  variables  and  categorical
ariables  (for  each  category).  Results  are  presented  for
he  overall  sample  and  for  the  subsets  of  patients  with
ubjective  and  objective  BPPV.  To  test  for  significant  dif-
erences  for  each  of  the  study  variables  between  patients
ith  subjective  and  objective  BPPV,  we  performed  the
ann--Whitney  U  test  for  numerical  variables  and  the  Fisher
xact  test  for  categorical  variables.  A  multivariate  logis-
ic  regression  model  was  built  to  explore  factors  associated
ith  the  presence  of  nystagmus.  The  explanatory  varia-
les  included  in  the  initial  model  were  age,  sex,  time  since
nset  of  symptoms,  number  of  previous  episodes  consistent
ith  BPPV,  self-reported  severity  of  symptoms,  history  of
 recent  viral  infection,  traumatic  brain  injury,  headache,
nxiety/depression,  hypertension,  diabetes  mellitus,  dys-
ipidemia,  cardiovascular  disease,  altered  thyroid  function,
steoporosis,  cervical  spondylosis,  neck  pain,  pharmacologic
reatment  of  vertigo  symptoms,  and  treatment  with  ben-
odiazepines,  anti-depressants,  and  antihypertensives.  The
kaike  Information  Criterion  (AIC)  was  used  to  select  the
est  fit-model.  This  process  involved  excluding  the  differ-
nt  variables  in  a  step-wise  fashion  and  choosing  the  model
ith  the  smallest  AIC,  i.e.,  an  AIC  that  was  not  reduced  fur-
her  by  the  exclusion  of  additional  variables.  The  selected
odel  was  retested,  again  using  the  AIC,  to  see  if  reintro-
uction  of  any  of  the  variables  reduced  the  AIC  further.  We
id  not  test  for  the  effect  of  interactions  between  variables.
esults
ig.  1  shows  study  flowchart.
We  included  134  patients  (76.1%  women)  with  a  median
ge  of  52  years  (interquartile  range  [IQR],  38.2--68.0  years).
ccording  to  the  baseline  DHT,  59.7%  of  the  patients  had
ubjective  BPPV  and  40.3%  had  objective  BPPV  (Table  1).
Patients  with  objective  BPPV  were  more  likely  to  have
 history  of  hypertension  (p  =  0.043)  or  to  be  on  treatment
ith  antihypertensives  (p  =  0.046).  We  also  detected  a  ten-
ency  toward  a  history  of  cervical  spondylosis  (p  =  0.059).
o  significant  differences  were  found  between  the  groups
or  any  of  the  other  variables.
In  the  multivariate  analysis  (Table  2),  patients  with  cer-
ical  spondylosis  were  more  likely  to  have  objective  BPPV
odds  ratio  [OR]  =  3.94;  95%  CI:  1.28--13.64;  p  =  0.021)  and
o  were  those  receiving  antihypertensives  (OR  =  3.02;  95%
I  =  1.14--8.41;  p  =  0.028).  Patients  on  benzodiazepines,  by
ontrast,  were  more  likely  to  present  subjective  BPPV  (OR,
.24;  0.06--0.77;  p  =  0.023).
iscussion
 high  proportion  of  the  primary  care  patients  in  our  series
59.7%)  had  subjective  BPPV.  Cervical  spondylosis  (OR  =  3.94)
nd  antihypertensive  therapy  (OR  =  3.02)  were  significan-
ly  associated  with  objective  BPPV,  while  treatment  with
enzodiazepines  was  significantly  associated  with  subjective
PPV  (OR  =  0.24).
























































Figure  1  
The  DHT  is  considered  the  gold  standard  for  diag-
osing  posterior  canal  BPPV,  but  the  reliability  of  the
iagnosis  is  strengthened  when  both  vertigo  and  nystag-
us  areobserved.11,15 In  a  study  by  Balatsouras,5 63  patients
ad  an  initial  diagnosis  of  subjective  BPPV  based  on  physi-
al  examination  findings.  However,  additional  testing  with
ideonystagmography  on  the  morning  after  recruitment
howed  that  21  of  these  patients  actually  had  mild  nystag-
us  that  was  not  visible  to  the  naked  eye.  Accordingly,  33%
f  these  patients  were  rediagnosed  with  objective  BPPV.
n  additional  11  patients  were  diagnosed  with  another
ondition  and  seven  were  left  undiagnosed.  Repositioning
aneuvers  were  almost  five  times  more  effective  in  patients
nitially  diagnosed  with  objective  BPPV  and  were  equally
ffective  in  patients  with  objective  and  subjective  BPPV
ollowing  the  regrouping  according  to  the  results  of  the
ideonystagmography  tests.  Subjective  BPPV  therefore  is
 less  reliable  diagnosis  than  objective  BPPV,  particularly
hen  based  on  the  results  of  the  DHT  only  (i.e.,  without
dditional  tests  such  as  videonystagmography).5
The  multivariate  analysis  in  our  study  showed  an  associa-
ion  between  objective  BPPV  and  cervical  spondylosis.  This
ink  between  BPPV  and  cervical  spondylosis  has  been  widely
ebated.  While  some  authors  question  whether  arthritis  of
he  neck  can  cause  BPPV,16 others  claim  that  it  can  as  it
ould  reduce  blood  flow  in  this  area,17 resulting  in  altered
culovestibular  reflexes  (on  which  nystagmus  depends)  and
ossibly  vertigo.18The  results  of  our  study  also  show  that  patients  with
bjective  BPPV  are  three  times  more  likely  than  those  with
ubjective  BPPV  to  be  on  antihypertensive  therapy.  The  asso-







lsewhere  and  was  first  highlighted  by  Brevern  et  al.19
ther  studies  have  shown  that  hypertension  can  increase
PPV  recurrence 20and  time  to  diagnosis.21 In  our  series,
PPV  was  associated  with  hypertension  in  the  bivariate
nalysis  and  antihypertensive  therapy  in  the  multivari-
te  analysis.  Hypertensive  patients  under  pharmacological
reatment  are  probably  more  representative  of  the  hyper-
ensive  population  in  general.  In  our  series,  treatment  with
enzodiazepines  was  significantly  associated  with  subjec-
ive  BBPV.  In  a  prospective  case-control  study  published  in
ctober  2018,  no  association  was  found  between  the  use  of
nti-vertigo  drugs  (betahistine  and  sulpride)  and  the  pres-
nce  or  absence  of  nystagmus.22 Our  findings,  by  contrast,
re  consistent  with  those  of  Tan  et  al.,23 who  found  higher
ates  of  vestibular  suppressant  medication  use  in  patients
ho  tested  positive  for  vertigo  on  positional  testing  than
n  those  who  tested  positive  for  both  vertigo  and  nystag-
us.  When  the  patients  were  retested  following  withdrawal
f  medication  (mostly  benzodiazepines  and  antihistamines),
0%  showed  nystagmus  (i.e.,  they  had  typical  BPPV).  As
urrent  guidelines  do  not  recommend  pharmacologic  treat-
ent  of  BPPV,24 anti-vertigo  medication  can  be  withdrawn
n  patients  with  an  equivocal  diagnosis  and  tests  repeated
ithin  approximately  a week.
imitationshe  original  study  on  which  the  results  of  this  study  are
ased  was  designed  to  evaluate  the  effectiveness  of  the
pley  maneuver  in  primary  care,  not  to  compare  factors
ssociated  with  the  presence  or  absence  of  baseline
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Table  1  Patient  characteristics  for  the  total  group  and  by  subgroups  of  patients  with  subjective  BPPV  (vertigo  only)  and
objective BPPV  (vertigo  and  nystagmus)  in  the  Dix-Hallpike  text.
n  Total  Subjective  BPPV  (n  =  80)  Objective  BPPV  (n  =  54)  p  value
Median  age  (IQR),  y  134  52.0  (38.2,  68.0)  49.0  (37.0,  65.2)  56.0  (39.0,  70.0)  0.160
Age, n  (%)  134  0.203
18--40 y  38  (28.4%)  23  (28.7%)  15  (27.8%)
41--60 y 43  (32.1%)  28  (35.0%)  15  (27.8%)
61--80 y 50  (37.3%) 29  (36.2%)  21  (38.9%)
81--96 y 3  (2.2%) 0  (0.0%) 3  (5.6%)
Women, n  (%) 134  102  (76.1%) 63  (78.8%) 39  (72.2%) 0.414
Median time  since  onset
of symptoms  (IQR),
days
134  11.0  (5.0,  31.0)  8.0  (4.0,  30.2)  15.0  (7.0,  32.5)  0.295
Previous episodes  of
vertigo,  n  (%)
133  63  (47.4%)  36  (45.0%)  27  (50.9%)  0.595
Median severity  of
vertigo  symptoms
(Likert  scale,  0--10)
134  7.0  [6.0,  8.0] 7.0  [6.0,  8.0] 8.0  [6.2,  8.8] 0.250
Medical history,  n  (%)
Viral  infection  in
previous  4  weeks
134  31  (23.1%)  19  (23.8%)  12  (22.2%)  1.000
Traumatic brain  injury  134  7  (5.2%)  3  (3.8%)  4  (7.4%)  0.439
Headache 134  48  (35.8%)  25  (31.2%)  23  (42.6%)  0.202
Anxiety 130  33  (25.4%)  19  (24.7%)  14  (26.4%)  0.840
Depression 130  30  (23.1%)  16  (20.8%)  14  (26.4%)  0.527
Hypertension  134  34  (25.4%)  15  (18.8%)  19  (35.2%)  0.043
Diabetes mellitus  130  19  (14.6%)  8  (10.4%)  11  (20.8%)  0.130
Dyslipidemia  134  57  (42.5%)  31  (38.8%)  26  (48.1%)  0.292
Cardiovascular  disease 134  6  (4.5%)  3  (3.8%)  3  (5.6%)  0.685
Altered thyroid
function
134  6  (4.5%)  4  (5.0%)  2  (3.7%)  1.000
Osteoporosis  134  16  (11.9%) 11  (13.8%)  5  (9.3%)  0.589
Cervical spondylosis 134  22  (16.4%) 9  (11.2%) 13  (24.1%)  0.059
Neck pain 134  64  (47.8%) 35  (43.8%)  29  (53.7%)  0.293
Pharmacologic
treatment for  BPPV,  n
(%)
134  0.468
None 56  (41.8%)  37  (46.2%)  19  (35.2%)
Betahistine  as
monotherapy
69  (51.5%)  37  (46.2%)  32  (59.3%)
Betahistine
combination  therapy
2  (1.5%)  1  (1.2%)  1  (1.9%)
Other anti-vertigo
drugs
7  (5.2%)  5  (6.2%)  2  (3.7%)
Other treatments,  n  (%)
Benzodiazepines  134  24  (17.9%)  16  (20.0%)  8  (14.8%)  0.498
Antidepressants  134  27  (20.1%)  13  (16.2%)  14  (25.9%)  0.192









Abbreviations:  BPPV: benign paroxysmal positional vertigo; IQR: i
ystagmus  in  patients  with  BPPV.  Nonetheless,  because
PPV  is  so  common  in  primary  care  and  because  there  is
 dearth  of  literature  on  DHT  responses  in  this  setting,
e  believe  that  this  substudy  is  important  as  it  could  help





The  high  prevalence  of  subjective  BPPV  observed  in  our
eries  is  logical  considering  that  GPs  see  more  cases  of  mild
PPV  (without  nystagmus),  have  less  experience  in  detect-ng  these  cases,  and  lack  the  equipment  for  doing  so  (e.g.,
renzel  goggles  and  videonystagmography).
J.L.B.  Moreno,  R.C.  Muñoz,  Y.R.  Matos  et  al.
Table  2  Multivariate  regression  analysis  of  predictors  of  nystagmus  (without  consideration  of  interactions).
OR  (95%  CI)  p  value
Independent  variable  0.72  (0.32,  1.61)  0.430
Sex Male  (reference)
Female  0.57  (0.23,  1.38)  0.209
Treatment with  benzodiazepines  0.24  (0.06,  0.77)  0.023
Treatment  with  antidepressants  2.68  (0.94,  8.06)  0.070
Treatment  with  antihypertensives 3.02  (1.14,  8.41)  0.028
Traumatic  brain  injury 3.60  (0.60,  23.95) 0.159
Osteoporosis  0.27  (0.05,  1.03) 0.072
Cervical spondylosis  3.94  (1.28,  13.64) 0.021
Best-fit model according to the Akaike Information Criterion. The initial model included age, sex, time since onset of symptions, number














































hypertension, diabetes mellitus, dyslipidemia, cardiovascular dise
pain, pharmacological treatment of vertigo symptoms, and treatm
onclusion
PPV  is  related  in  the  present  study  with  cervical  spondy-
osis  and  arterial  hypertension.  Association  of  BPPV  with
ardiovascular  risk  factors  makes  recommendable  monitor-
ng  these  patients.  Treatment  with  benzodiazepines  can
orsen  the  detection  of  nystagmus  so  it  is  never  indicated  in
hese  patients.  Future  research  should  focus  on  determining
hether  interrupt  sedatives  medication  before  testing  BPPV
ould  improve  nystagmus  detection,  providing  more  reliable
iagnoses  and  better  prognosis  for  patients.
Keypoints
What  is  known  about  the  topic
• Posterior  canal  benign  paroxysmal  positional  vertigo
(BPPV)  is  the  most  common  type  of  vertigo  seen  in
primary  care  settings.
•  This  condition  can  be  adequately  diagnosed  and
treated  with  the  Dix-Hallpike  (DH)  test  and  canal
repositioning  maneuvers.
•  The  DHT  provokes  vertigo  in  the  absence  of  observ-
able  nystagmus  in  a  considerable  proportion  of  cases
(11%--48%).
What  this  study  adds
• The  prevalence  of  subjective  BPPV  detected  in  our
primary  care  setting  (59.71%)  was  higher  than  that
observed  in  previous  studies
•  Patients  with  subjective  BPPV  are  more  likely  to  be
taking  benzodiazepines.
•  Patients  with  objective  BPPV  (vertigo  plus  nystagmus
in  the  DHT)  are  more  likely  to  have  cervical  spondy-




altered thyroid function, osteoporosis, cervical spondylosis, neck
with benzodiazepines, anti-depressants, and antihypertensives.
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